VOR and 688331.SS Related Headlines
Go Back- Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
- Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
- VOR Bio's partner achieves primary endpoint in phase 3 Sjogren's disease trial
- Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor
VOR and 688331.SS Related Press Releases
Go Back- Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
- Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
- Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor
